Actinium Pharmaceuticals (NYSE:ATNM) Stock Rating Upgraded by StockNews.com

Actinium Pharmaceuticals (NYSE:ATNM) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

Several other equities analysts have also recently weighed in on ATNM. Maxim Group lowered their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. HC Wainwright decreased their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, B. Riley cut Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $16.00 to $2.00 in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.40.

Actinium Pharmaceuticals Price Performance

NYSE ATNM opened at $1.57 on Tuesday. The company’s fifty day moving average price is $2.11. The company has a market cap of $46.61 million, a PE ratio of -0.92 and a beta of 0.14. Actinium Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02. As a group, analysts expect that Actinium Pharmaceuticals will post -1.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ATNM. Sanders Morris Harris LLC bought a new position in shares of Actinium Pharmaceuticals in the 1st quarter valued at about $78,000. Vanguard Group Inc. lifted its stake in Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares during the last quarter. Virtu Financial LLC lifted its stake in Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after purchasing an additional 62,459 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Actinium Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after purchasing an additional 19,035 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the last quarter. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).